Anbio Biotechnology is marking its entry into the European market with its flagship product, the AF-100 C, a groundbreaking compact fluorescent immunoassay analyser designed to revolutionise the field of point-of-care diagnostics. Equipped with an extensive arsenal of over 70 assays, the AF-100 C is set to amplify the effectiveness of healthcare practitioners across the EU, thereby enhancing patient diagnosis and care.
With an eye on expanding its footprint in the European Union, Anbio Biotechnology (Anbio), a pioneer in the global arena of in vitro diagnostics, proudly presents its comprehensive “Point of Care” product range to the EU. This initiative signifies a momentous stride for Anbio, creating avenues for partnerships with EU distributors and medical professionals, and illustrating the company’s resolve to supply the EU with forefront diagnostic innovations.
Anbio, known for its innovative edge and commitment to quality, has progressed beyond its initial identification as a supplier of Covid test kits to a dynamic manufacturer and developer of a vast array of diagnostic tools. “Our mission is to revolutionize diagnostics by offering tailored and accessible solutions, including laboratory, wellness, at-home, and point-of-care diagnostics. We are committed to affordability and continuous innovation in life sciences that serve to advance human heath,” stated Michael Lau, CEO of Anbio.
State-of-the-art Analyzer Provides Access to Over 70 Key Diagnostic Tests
The AF-100 C analyzer, a leading single-channel, portable, rechargeable compact fluorescent Immunoassay (FIA) analyzer, is pivotal to Anbio’s promotional drive in the EU. This sophisticated device, along with over 70 CE-marked assays for a broad spectrum of analytes including markers for inflammation, diabetes, cancer, hormones, enzymes, and infectious diseases, is anticipated to dramatically transform the clinical diagnostics landscape within the EU.
“The Anbio AF-100 C is a game-changer for clinical diagnostics, supplying healthcare providers with a cost-effective, comprehensive, and reliable solution for rapid point-of-care testing,” Lau highlighted. The AF-100 C’s compact size belies its high throughput capabilities, making it an excellent fit for diverse clinical settings, from local clinics to bustling emergency departments. Its intuitive design and robust battery, capable of sustaining up to 8 hours of continuous operation, ensure that healthcare workers can offer superior patient care with utmost efficiency and accuracy.
Rapid, Precise Diagnostics Aim to Elevate Patient Healthcare Outcomes
Anbio’s extensive FIA catalogue, capable of producing swift results within a 3 to 15-minute window, represents a significant leap in diagnostic technology. Featuring reagents that employ RFID chip technology for unparalleled accuracy and capable of being stored at ambient temperature for up to two years, Anbio is strategically positioned to meet the European healthcare sector’s immediate demands.
As Anbio Biotechnology ventures into the EU market, it invites distributors and healthcare practitioners to explore its avant-garde diagnostic offerings. Committed to advancing patient care through affordable, accurate, and dependable diagnostics, Anbio aspires to collaborate with healthcare professionals across the European Union.